Respiratory drug discovery specialist Synairgen (LON:SNG) saw its shares climb by 7.29% to 15.82p (as at 13:30 BST) after the company announced positive developments from phase II trials for a antiviral treatment for chronic obstructive pulmonary disease.
Get the latest from Master Investor directly in your inbox – Sign-up HERE for FREE
Management said that the treatment had been well tolerated during the tests and had shown statistically significant increases in antiviral biomarkers in patients. Testing is scheduled to continue over the winter with the company aiming to enroll 80 subjects to check various endpoints.